DIAアカウントをお持ちの場合、サインインしてください。

サインイン

ユーザーIDをお忘れですか? or パスワードをお忘れですか?

McCormick Place

2017年6月18日 (日) 午前 8:30 - 2017年6月22日 (木) 午後 12:45

2301 South Martin Luther King Jr. Drive, Gate 4, Chicago, IL 60616

DIA 2017 Annual Meeting

Patient-Centric Development Assessment

Session Chair(s)

Mahesh R. Ramanadham, PHARMD, MBA

Mahesh R. Ramanadham, PHARMD, MBA

Deputy Director, Office of Policy for Pharmaceutical Quality, OPQ, CDER

FDA, United States

Patient-centric product quality requires that patient needs are incorporated effectively during product development and assessment activities. Establishing a Target Product Profile is essential to the design and control of a product platform in order to accommodate and deliver patient needs throughout the product life cycle. As well, incorporating patient centric needs into product quality assessment ensures outcomes that are risk based and balanced. This session will explore industry and agency practices and expectations in implementing patient-centric product quality development and assessment approaches.

Learning Objective : Explain the importance of the target product profile to the life cycle of the product

Speaker(s)

Michael R. De Felippis, PHD

Patient-Focused Biopharmaceutical Control Strategies

Michael R. De Felippis, PHD

Eli Lilly and Company , United States

Senior Research Fellow, Biopharmaceutical Research and Development

Diane J. Zezza

Incorporating Clinical Needs of Products into Quality Assessment

Diane J. Zezza

Novartis Pharmaceuticals Corporation, United States

Vice President and Global Head, Regulatory CMC

Mahesh R. Ramanadham, PHARMD, MBA

Patient Centric Assessment

Mahesh R. Ramanadham, PHARMD, MBA

FDA, United States

Deputy Director, Office of Policy for Pharmaceutical Quality, OPQ, CDER

最新情報や機会を逃さないで

DIAのメールを購読すれば、常に最新の業界情報やイベント情報を得ることができます。